X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

ALKEM LABORATORIES vs GSK PHARMA - Comparison Results

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    ALKEM LABORATORIES GSK PHARMA ALKEM LABORATORIES/
GSK PHARMA
 
P/E (TTM) x - 53.8 - View Chart
P/BV x 5.9 10.7 55.1% View Chart
Dividend Yield % 0.7 2.7 27.3%  

Financials

 ALKEM LABORATORIES   GSK PHARMA
EQUITY SHARE DATA
    ALKEM LABORATORIES
Mar-16
GSK PHARMA
Mar-18
ALKEM LABORATORIES/
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,5892,760 57.6%   
Low Rs1,2322,040 60.4%   
Sales per share (Unadj.) Rs417.5339.0 123.1%  
Earnings per share (Unadj.) Rs56.341.4 135.9%  
Cash flow per share (Unadj.) Rs64.745.9 141.0%  
Dividends per share (Unadj.) Rs12.7035.00 36.3%  
Dividend yield (eoy) %0.91.5 61.7%  
Book value per share (Unadj.) Rs292.9242.9 120.6%  
Shares outstanding (eoy) m119.5784.70 141.2%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.47.1 47.7%   
Avg P/E ratio x25.157.9 43.2%  
P/CF ratio (eoy) x21.852.3 41.7%  
Price / Book Value ratio x4.89.9 48.7%  
Dividend payout %22.684.5 26.7%   
Avg Mkt Cap Rs m168,653203,280 83.0%   
No. of employees `000NANA-   
Total wages/salary Rs m9,1715,234 175.2%   
Avg. sales/employee Rs ThNMNM-  
Avg. wages/employee Rs ThNMNM-  
Avg. net profit/employee Rs ThNMNM-  
INCOME DATA
Net Sales Rs m49,91528,715 173.8%  
Other income Rs m1,645545 301.6%   
Total revenues Rs m51,56129,260 176.2%   
Gross profit Rs m8,4825,059 167.7%  
Depreciation Rs m1,006380 264.7%   
Interest Rs m6712 33,530.0%   
Profit before tax Rs m8,4515,222 161.8%   
Minority Interest Rs m-1140-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0178 0.0%   
Tax Rs m1,6061,892 84.9%   
Profit after tax Rs m6,7313,508 191.9%  
Gross profit margin %17.017.6 96.5%  
Effective tax rate %19.036.2 52.5%   
Net profit margin %13.512.2 110.4%  
BALANCE SHEET DATA
Current assets Rs m27,06221,815 124.1%   
Current liabilities Rs m15,32415,999 95.8%   
Net working cap to sales %23.520.3 116.1%  
Current ratio x1.81.4 129.5%  
Inventory Days Days6764 104.6%  
Debtors Days Days4119 220.9%  
Net fixed assets Rs m12,61012,475 101.1%   
Share capital Rs m239847 28.2%   
"Free" reserves Rs m34,49019,726 174.8%   
Net worth Rs m35,02720,573 170.3%   
Long term debt Rs m1,2126 20,193.3%   
Total assets Rs m54,38739,475 137.8%  
Interest coverage x13.62,612.0 0.5%   
Debt to equity ratio x00 11,860.8%  
Sales to assets ratio x0.90.7 126.2%   
Return on assets %13.68.9 153.1%  
Return on equity %19.217.1 112.7%  
Return on capital %24.926.2 94.7%  
Exports to sales %12.90-   
Imports to sales %3.10-   
Exports (fob) Rs m6,461NA-   
Imports (cif) Rs m1,540NA-   
Fx inflow Rs m6,563564 1,163.7%   
Fx outflow Rs m3,0127,429 40.5%   
Net fx Rs m3,552-6,865 -51.7%   
CASH FLOW
From Operations Rs m7,2594,728 153.5%  
From Investments Rs m1,864-1,042 -178.9%  
From Financial Activity Rs m-9,273-3,066 302.4%  
Net Cashflow Rs m-150620 -24.2%  

Share Holding

Indian Promoters % 66.9 0.0 -  
Foreign collaborators % 0.0 50.7 -  
Indian inst/Mut Fund % 33.1 10.2 324.5%  
FIIs % 0.0 23.8 -  
ADR/GDR % 0.0 0.0 -  
Free float % 0.0 15.4 -  
Shareholders   68,381 102,036 67.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare ALKEM LABORATORIES With:   ALEMBIC LTD  SUN PHARMA  DR. DATSONS LABS  DR. REDDYS LAB  SANOFI INDIA  

Compare ALKEM LABORATORIES With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Flat; Realty and Energy Stocks Gain(09:30 am)

Asian stock markets are higher today as Chinese and Hong Kong shares show gains. The Shanghai Composite is up 0.4% while the Hang Seng is up 0.3%.

Related Views on News

GSK PHARMA Announces Quarterly Results (3QFY19); Net Profit Up 26.0% (Quarterly Result Update)

Feb 5, 2019 | Updated on Feb 5, 2019

For the quarter ended December 2018, GSK PHARMA has posted a net profit of Rs 1 bn (up 26.0% YoY). Sales on the other hand came in at Rs 8 bn (up 17.3% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY19); Net Profit Down 22.7% (Quarterly Result Update)

Oct 23, 2018 | Updated on Oct 23, 2018

For the quarter ended September 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 22.7% YoY). Sales on the other hand came in at Rs 8 bn (down 2.4% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY19); Net Profit Up 235.3% (Quarterly Result Update)

Jul 26, 2018 | Updated on Jul 26, 2018

For the quarter ended June 2018, GSK PHARMA has posted a net profit of Rs 886 m (up 235.3% YoY). Sales on the other hand came in at Rs 7 bn (up 21.2% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA Announces Quarterly Results (4QFY18); Net Profit Down 6.4% (Quarterly Result Update)

May 28, 2018 | Updated on May 28, 2018

For the quarter ended March 2018, GSK PHARMA has posted a net profit of Rs 1 bn (down 6.4% YoY). Sales on the other hand came in at Rs 7 bn (down 4.5% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

More Views on News

Most Popular

My Top 3 Defence Stocks to Buy Now(The 5 Minute Wrapup)

Mar 19, 2019

The urgency to privatise India's defence sector to make India self-reliant was never as strong as it is today.

This Small Cap Stock Could Offer Triple Digit Gains from its Current Price(Profit Hunter)

Mar 19, 2019

If you are still waiting for signals, remember, there is no correct timing, only right time to Buy stocks. For select small caps, that time is now.

5 Fundamentally Strong Stocks to Pick for Trading Today(Profit Hunter)

Mar 15, 2019

5 fundamentally strong stocks one could buy to trade in this market right now. Make sure you grab the chance this strongly rallying market offers.

Elections Don't Matter!(The Honest Truth)

Mar 13, 2019

Ajit Dayal shows us why from the point of view of the Indian economy, elections don't matter.

Two Growth Stocks that Doubled in a Little Over 12 Months!(The 5 Minute Wrapup)

Mar 13, 2019

The elements that fueled profit growth for these two companies led to a surge in their stock prices.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

ALKEM LABORATORIES SHARE PRICE


Mar 26, 2019 12:11 PM

TRACK ALKEM LABORATORIES

  • Track your investment in ALKEM LABORATORIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON ALKEM LABORATORIES

ALKEM LABORATORIES - FDC LTD. COMPARISON

COMPARE ALKEM LABORATORIES WITH

MARKET STATS